ArticleDevelopment (Cambridge, England)2026
The roles of the acetyltransferase domains of the chromatin regulators KAT6A and KAT6B in vivo.
Article in Development (Cambridge, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
KAT6A (MOZ) and KAT6B (QKF/MORF) are related histone lysine acetyltransferases (KATs) that have a high degree of functional redundancy during development. In the absence of KAT6A, embryos undergo an anterior homeotic transformation of the axial skeleton, develop an interrupted aortic arch, have ventricular septal defects and fail to form definitive hematopoietic stem cells. KAT6B has roles in brain, skeletal and hematopoietic system development. Because loss of KAT6A leads to highly penetrant phenotypes, this allows us to determine whether the acetylation function is essential for all activities. We show that loss of acetyltransferase activity did not phenocopy the loss of the KAT6A protein in mice. Although mutation of the KAT domains of both KAT6A and KAT6B together increased the severity of phenotypes observed, these were milder than complete KAT6A loss of function. KAT domain mutants displayed ventricular septal defects and reduced (but not eliminated) hematopoietic stem cell activity. However, they did not display homeotic transformations or aortic arch defects, suggesting that, while acetylation is important for some functions, others can proceed without this activity. Accordingly, KAT6 proteins appear to have functions beyond acetylation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.